Montelukast

Montelukast: Anti-Inflammatory Properties and Clinical Applications

Report by Dr M Morgan MB BS BSc July 2025

Mechanism of Action and Anti-Inflammatory Effects

Montelukast is a cysteinyl leukotriene receptor antagonist that works by blocking the CysLT1 receptor, thereby inhibiting the action of inflammatory mediators released primarily from mast cells, eosinophils, and macrophages1 2. The drug demonstrates significant anti-inflammatory properties through multiple mechanisms:

The primary anti-inflammatory mechanism involves blocking leukotriene-mediated inflammation, including bronchoconstriction, increased vascular permeability, and mucus secretion1. Beyond its primary mechanism, montelukast possesses secondary anti-inflammatory properties that include interference with nuclear factor kappa B activation in immune cells, promotion of sustained interleukin-10 production, and inhibition of signalling pathways triggered by P2Y receptors1.

Research has shown that montelukast inhibits neutrophil pro-inflammatory activity through a cyclic AMP-dependent mechanism1. The drug significantly reduces the generation of reactive oxygen species and leukotriene B4 by chemoattractant-activated neutrophils, as well as elastase release. These effects are achieved through alterations in cellular calcium handling and elevation of basal cyclic adenosine monophosphate levels1.

Montelukast in Mast Cell Activation Syndrome (MCAS)

Montelukast has emerged as a valuable therapeutic option for patients with MCAS, a condition characterised by inappropriate mast cell activation and mediator release. The drug's effectiveness in MCAS stems from its ability to block the effects of leukotriene C4 (LTC4), one of the key mediators released by activated mast cells3 4.

In MCAS treatment protocols, montelukast is typically dosed at 10mg once to twice daily4. The drug functions as both a mast cell stabiliser and a leukotriene receptor antagonist, helping to reduce wheezing and abdominal cramping associated with mast cell activation3 5. Clinical experience suggests that montelukast can be particularly beneficial for patients experiencing gastrointestinal symptoms, respiratory manifestations, and other systemic symptoms of MCAS6.

Research has demonstrated that montelukast can inhibit mast cell degranulation in stress-induced conditions. A study using water avoidance stress in rats showed that chronic montelukast treatment reduced stress-induced infiltration and activation of mast cells in the dermis, suggesting potential therapeutic applications in stress-related mast cell disorders7.

Clinical Benefits in MCAS Management

For MCAS patients, montelukast offers several therapeutic advantages:

Mediator Blockade: The drug effectively blocks the action of cysteinyl leukotrienes, which are key inflammatory mediators released during mast cell activation2 3. This blockade can significantly reduce respiratory symptoms, gastrointestinal manifestations, and other systemic effects of mast cell activation.

Combination Therapy: Montelukast is frequently used alongside other MCAS treatments, including H1 and H2 antihistamines, mast cell stabilisers like sodium cromoglicate, and other supportive medications4 8. This multi-modal approach provides comprehensive symptom control by targeting different aspects of mast cell activation.

Tolerability: The drug demonstrates good tolerability in most patients, with a safety profile that makes it suitable for long-term use in chronic conditions like MCAS9 10.

Unexpected Benefits: Cognitive and Neuroprotective Effects

Recent research has revealed potentially significant neuroprotective and cognitive benefits of montelukast, representing an unexpected therapeutic application beyond its established anti-inflammatory uses.

Dementia Prevention and Cognitive Enhancement

Several observational studies suggest that montelukast may have protective effects against dementia. A large retrospective cohort study in Japan found that patients prescribed leukotriene receptor antagonists had a 42% reduced risk of developing dementia compared to those not using these medications (adjusted hazard ratio=0.42, 95% confidence interval=0.20-0.87)11. Similarly, a Norwegian prescription database study suggested that montelukast users had lower dementia risk compared to those taking other asthma medications12.

The neuroprotective mechanisms underlying these effects appear to involve multiple pathways:

Neuroinflammation Reduction: Montelukast crosses the blood-brain barrier and blocks leukotriene receptors expressed throughout the central nervous system, particularly on microglial cells, astrocytes, and neurons13. By inhibiting these receptors, the drug may reduce neuroinflammation, a key contributor to neurodegenerative diseases14 15.

Blood-Brain Barrier Protection: Animal studies have shown that montelukast can restore blood-brain barrier integrity and enhance neurogenesis in aged brains13. These effects were accompanied by improved learning and memory functions in experimental models14.

Cellular Protection: The drug has demonstrated protective effects against neuronal cell death, particularly in models of cerebral ischemia and neurotoxicity14 15. These protective effects may contribute to its potential role in preventing cognitive decline.

Clinical Evidence and Limitations

A case series of 17 patients with varying degrees of memory impairment treated with high-dose montelukast (80mg daily in divided doses) showed subjective improvement in memory and recall in patients with mild cognitive impairment14 15. Patients with dementia showed reduced agitation but limited memory improvement at the doses used.

However, controlled clinical trials have produced mixed results. A small study of 12 asthma patients found no significant cognitive improvements after 8 weeks of standard-dose montelukast treatment13 16. The researchers noted that longer treatment duration and higher doses might be necessary to achieve cognitive benefits.

Safety Considerations and Neuropsychiatric Effects

While montelukast demonstrates promising therapeutic benefits, it carries a black box warning for serious neuropsychiatric events, particularly in children and adolescents17 18. These adverse effects can include depression, anxiety, agitation, aggressive behaviour, hallucinations, and suicidal ideation17 19.

The neuropsychiatric effects appear to be dose-dependent and reversible upon discontinuation20. Healthcare providers must carefully weigh the benefits against potential risks, particularly when considering montelukast for MCAS patients who may already be dealing with chronic illness-related psychological stressors.

Additional Therapeutic Applications

Beyond its primary indications and emerging cognitive benefits, montelukast has demonstrated efficacy in several other conditions:

Atopic Dermatitis: Limited evidence suggests potential benefits in moderate-to-severe atopic dermatitis, though results are mixed21.

Rheumatoid Arthritis: Research indicates that montelukast can inhibit inflammatory responses in rheumatoid arthritis by decreasing secretion of inflammatory cytokines and matrix metalloproteinases22.

Gastroprotection: Studies have shown that montelukast can enhance the anti-inflammatory effects of NSAIDs while providing gastroprotective benefits23 24.

Clinical Implications and Future Directions

The evidence supporting montelukast's use in MCAS is substantial, with the drug providing effective symptom control through leukotriene blockade and potential mast cell stabilisation effects. The emerging data on cognitive benefits, while promising, requires further investigation through larger, controlled clinical trials.

For MCAS patients, montelukast represents a valuable addition to comprehensive treatment regimens, offering both immediate symptom relief and potentially longer-term neuroprotective benefits. However, careful monitoring for neuropsychiatric effects is essential, particularly during treatment initiation and dose adjustments.

The drug's multifaceted anti-inflammatory properties extend beyond its primary mechanism, offering potential benefits in various inflammatory conditions. As research continues to elucidate these mechanisms, montelukast may find expanded therapeutic applications in inflammatory and neurodegenerative diseases.

Healthcare providers should consider montelukast as part of a comprehensive MCAS management strategy, while remaining vigilant for potential adverse effects and monitoring for both therapeutic benefits and any concerning neuropsychiatric symptoms.

Export

Rewrite

Can montelukast's anti-inflammatory effects benefit mast cell activation syndrome

Does montelukast have unexpected benefits like cognitive protection or dementia risk reduction

How does montelukast's mechanism influence mast cell activity beyond leukotriene antagonism

Are there studies showing montelukast improves symptoms in MCAS patients

Could montelukast’s cAMP elevation offer neuroprotective effects against dementia

American English